Treatment of hepatitis C virus–associated mixed cryoglobulinemia with direct‐acting antiviral agents
Meghan E. Sise, Allyson K. Bloom, Jessica Wisocky, Ming V. Lin, Jenna L. Gustafson, Andrew L. Lundquist, David Steele, Michael Thiim, Winfred W. Williams, Nikroo Hashemi, Arthur Y. Kim, Ravi Thadhani, Raymond T. Chung – 17 October 2015 – Hepatitis C virus (HCV) is the most common cause of mixed cryoglobulinemia syndrome (MCS). The efficacy and safety of all‐oral direct‐acting antiviral (DAA) therapy in HCV‐associated MCS (HCV‐MCS) is largely unknown.